Intra-Cellular Therapies Inc (OQ:ITCI)

Jun 18, 2024 07:30 am ET
Intra-Cellular Therapies Announces Positive Topline Results in Second Phase 3 Trial Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced positive topline results from Study 502...
May 29, 2024 08:00 am ET
Intra-Cellular Therapies to Present at the Jefferies Global Healthcare Conference
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive...
May 23, 2024 08:00 am ET
Intra-Cellular Therapies Highlights Data Presentations at the American Society of Clinical Psychopharmacology Annual Meeting
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today highlights data presentations at the American Society of...
May 08, 2024 08:00 am ET
Intra-Cellular Therapies to Participate in Two Upcoming Investor Conferences
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will participate in two upcoming...
May 07, 2024 07:30 am ET
Intra-Cellular Therapies Reports First Quarter 2024 Financial Results
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the first quarter...
Apr 30, 2024 08:00 am ET
Intra-Cellular Therapies to Host First Quarter 2024 Financial Results Conference Call and Webcast
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced it will host a conference call and live webcast...
Apr 24, 2024 04:01 pm ET
Intra-Cellular Therapies Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) (“Intra-Cellular Therapies”), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it has...
Apr 17, 2024 08:46 pm ET
Intra-Cellular Therapies Prices Public Offering of Common Stock
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) (“Intra-Cellular Therapies”), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the pricing of its...
Apr 16, 2024 04:06 pm ET
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) (“Intra-Cellular Therapies”), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it has...
Apr 16, 2024 07:00 am ET
Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced positive topline results from Study 501...
Mar 19, 2024 08:30 am ET
Intra-Cellular Therapies Announces Executive Appointments and Leadership Changes
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the promotion of Michael Halstead, J.D. to the...
Mar 06, 2024 08:00 am ET
Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will participate in three upcoming...
Feb 27, 2024 08:00 am ET
Intra-Cellular Therapies to Present at the 44th Annual TD Cowen Health Care Conference
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive...
Feb 22, 2024 07:30 am ET
Intra-Cellular Therapies Reports Fourth Quarter And Full-Year 2023 Financial Results And Provides Corporate Update
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the fourth quarter...
Feb 08, 2024 08:00 am ET
Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced it will host a conference call and live webcast...
Jan 02, 2024 08:00 am ET
Intra-Cellular Therapies to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive...
Dec 05, 2023 08:00 am ET
Intra-Cellular Therapies Highlights Data Presentations at the American College of Neuropsychopharmacology Annual Meeting
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced data presentations at the American College of...
Nov 15, 2023 08:00 am ET
Intra-Cellular Therapies to Present at the 6th Annual Evercore ISI HealthCONx Conference
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will present at the 6th Annual Evercore...
Nov 02, 2023 07:30 am ET
Intra-Cellular Therapies Reports Third Quarter 2023 Financial Results and Raises 2023 CAPLYTA Sales Guidance
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the third quarter...
Oct 31, 2023 08:00 am ET
Intra-Cellular Therapies to Participate in Two Upcoming Investor Conferences
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will participate in two upcoming...
Oct 26, 2023 08:00 am ET
Intra-Cellular Therapies to Host Third Quarter 2023 Financial Results Conference Call and Webcast
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced it will host a conference call and live webcast...
Sep 20, 2023 08:00 am ET
Intra-Cellular Therapies to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will present at the 2023 Cantor...
Sep 11, 2023 08:00 am ET
Intra-Cellular Therapies Announces Presentations at Psych Congress 2023 Including Positive Results from Study 403 in Mixed Features
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced several CAPLYTA data presentations at the 2023...
Sep 05, 2023 08:00 am ET
Intra-Cellular Therapies to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will present at the Morgan Stanley 21st...
Aug 04, 2023 08:00 am ET
Intra-Cellular Therapies to Present at the Canaccord Genuity 43rd Annual Growth Conference
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will present at the Canaccord Genuity...
Aug 03, 2023 07:30 am ET
Intra-Cellular Therapies Reports Second Quarter 2023 Financial Results and Raises 2023 CAPLYTA Sales Guidance
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the second quarter...
Jul 28, 2023 08:00 am ET
Intra-Cellular Therapies to Host Second Quarter 2023 Financial Results Conference Call and Webcast
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced it will host a conference call and live webcast...
Jun 05, 2023 08:00 am ET
Intra-Cellular Therapies to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will present at the Goldman Sachs 44th...
May 31, 2023 08:00 am ET
Intra-Cellular Therapies Announces CAPLYTA Data Presentations at the American Society of Clinical Psychopharmacology Annual Meeting
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced several CAPLYTA data presentations at the...
May 04, 2023 07:30 am ET
Intra-Cellular Therapies Reports First Quarter 2023 Financial Results and Provides Corporate Update
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the first quarter...
May 02, 2023 08:00 am ET
Intra-Cellular Therapies to Present at Two Upcoming Investor Conferences
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will present at two upcoming investor...
Apr 26, 2023 08:00 am ET
Intra-Cellular Therapies to Host First Quarter 2023 Financial Results Conference Call and Webcast
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced it will host a conference call and live webcast...
Apr 11, 2023 08:00 am ET
Intra-Cellular Therapies to Present at the 22nd Annual Needham Virtual Healthcare Conference
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive...
Mar 01, 2023 07:30 am ET
Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the fourth quarter and...
Feb 14, 2023 08:00 am ET
Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced it will host a conference call and live webcast...
Feb 08, 2023 08:00 am ET
Intra-Cellular Therapies to Present at the SVB Securities Global Biopharma Conference
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive...
Jan 03, 2023 08:00 am ET
Intra-Cellular Therapies to Present at the 41st Annual J.P. Morgan Healthcare Conference
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive...
Dec 08, 2022 08:00 am ET
Intra-Cellular Therapies Highlights New CAPLYTA Bipolar Depression Data Presentations at the American College of Neuropsychopharmacology 61st Annual Meeting
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced four data presentations at the American College...
Nov 10, 2022 08:00 am ET
Intra-Cellular Therapies to Participate at Two Upcoming Investor Conferences
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will participate at two upcoming...
Nov 03, 2022 07:30 am ET
Intra-Cellular Therapies Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the third quarter...
Oct 27, 2022 08:00 am ET
Intra-Cellular Therapies to Host Third Quarter 2022 Financial Results Conference Call and Webcast
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live...
Aug 09, 2022 07:30 am ET
Intra-Cellular Therapies Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the second quarter...
Aug 04, 2022 03:07 pm ET
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Intra-Cellular Therapies, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors
NEW YORK, Aug. 4, 2022 /PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Intra-Cellular Therapies, Inc. (NASDAQ: ITCI).
Aug 02, 2022 08:00 am ET
Intra-Cellular Therapies to Host Second Quarter 2022 Financial Results Conference Call and Webcast
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live...
Jun 18, 2022 03:30 pm ET
INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Intra-Cellular Therapies, Inc. with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / June 18, 2022 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors ofIntra-Cellular Therapies, Inc. ("Intra-Cellular" or "the Company") (NASDAQ:ITCI) for violations of the securities laws.
Jun 16, 2022 10:29 am ET
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Intra-Cellular Therapies, Inc. with Losses to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Intra-Cellular Therapies, Inc. (“Intra-Cellular” or “the Company”) (NASDAQ:
Jun 13, 2022 08:00 am ET
Intra-Cellular Therapies Highlights Lumateperone Bipolar Depression Data Presentations at the 2022 International Society for Bipolar Disorders (ISBD) Experience
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced data presentations at the 2022 International...
May 10, 2022 07:30 am ET
Intra-Cellular Therapies Reports First Quarter 2022 Financial Results and Provides Corporate Update
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the first quarter...
May 03, 2022 08:00 am ET
Intra-Cellular Therapies to Host First Quarter 2022 Financial Results Conference Call and Webcast
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live...
Apr 25, 2022 07:00 am ET
Intra-Cellular Therapies Announces FDA Approval of New Dosage Strengths for CAPLYTA® (lumateperone) for Specific Patient Populations
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA)...
Apr 21, 2022 08:00 am ET
Intra-Cellular Therapies Announces Appointment of E. Rene Salas to Board of Directors
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the appointment of E. Rene Salas to the...
Apr 05, 2022 08:00 am ET
Intra-Cellular Therapies to Present at the 21st Annual Needham Virtual Healthcare Conference
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive...
Mar 01, 2022 07:30 am ET
Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the fourth quarter and...
Feb 22, 2022 08:00 am ET
Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Webcast
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live...
Feb 10, 2022 08:00 am ET
Intra-Cellular Therapies to Present at the 11th Annual SVB Leerink Global Healthcare Conference
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive...
Jan 07, 2022 04:01 pm ET
Intra-Cellular Therapies Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the completion of its previously announced...
Jan 04, 2022 10:05 pm ET
Intra-Cellular Therapies Prices Public Offering of Common Stock
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the pricing of its previously announced...
Jan 03, 2022 04:01 pm ET
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it has commenced an underwritten public...
Jan 03, 2022 08:00 am ET
Intra-Cellular Therapies to Present at the 40th Annual J.P. Morgan Healthcare Conference
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive...
Dec 20, 2021 08:31 am ET
Thinking about buying stock in Intra-Cellular Therapies, Selecta Biosciences, Coherus Biosciences, ImmunityBio, or SeaChange International?
NEW YORK, Dec. 20, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ITCI, SELB, CHRS, IBRX, and SEAC.
Dec 20, 2021 06:47 am ET
Intra-Cellular Therapies Announces U.S. FDA Approval of CAPLYTA® (lumateperone) for the Treatment of Bipolar Depression in Adults
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA)...
Dec 06, 2021 04:01 pm ET
Intra-Cellular Therapies Mourns the Passing of Director, Dr. Richard Lerner
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, mourns the passing of one of our Directors, Richard Lerner, MD, a...
Nov 09, 2021 07:30 am ET
Intra-Cellular Therapies Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the third quarter...
Nov 02, 2021 08:00 am ET
Intra-Cellular Therapies to Host Third Quarter 2021 Financial Results Conference Call and Webcast
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live...
Oct 18, 2021 08:00 am ET
Intra-Cellular Therapies Announces Amended Start Time to Virtual Event on Wednesday, October 20
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the Company’s Virtual Event featuring highlights...
Oct 08, 2021 08:00 am ET
Intra-Cellular Therapies to Host a Virtual Event to Feature Highlights of Several of its Development Programs
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will host a virtual event to discuss the...
Sep 27, 2021 07:30 am ET
Intra-Cellular Therapies Announces Publication of Lumateperone Pivotal Phase 3 Study in Bipolar Depression in The American Journal of Psychiatry
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the publication of the results from its...
Sep 22, 2021 08:00 am ET
Intra-Cellular Therapies to Present at the 2021 Cantor Virtual Global Healthcare Conference
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive...
Sep 20, 2021 07:30 am ET
Intra-Cellular Therapies Announces Publications Highlighting Beneficial Effects of Phosphodiesterase Type I Inhibition with Lenrispodun (ITI-214) on Cardiovascular Function in Patients with Heart Fail
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) today highlights the publication of four manuscripts that report on the mechanism of action of lenrispodun (ITI-214) and the potential cardiovascular therapeutic effects of Phosphodiesterase Type I...
Aug 10, 2021 08:00 am ET
Intra-Cellular Therapies to Present at the Canaccord Genuity 41st Annual Growth Conference
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive...
Aug 09, 2021 07:30 am ET
Intra-Cellular Therapies Reports Second Quarter 2021 Financial Results and Provides Corporate Update
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the second quarter...
Aug 02, 2021 08:00 am ET
Intra-Cellular Therapies to Host Second Quarter 2021 Financial Results Conference Call and Webcast
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live...
Jun 07, 2021 08:00 am ET
CAPLYTA® (lumateperone) Schizophrenia Safety and Tolerability Profile Published in the Journal, International Clinical Psychopharmacology
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the article, "Safety and tolerability of...
May 26, 2021 08:00 am ET
Intra-Cellular Therapies to Present at Two Upcoming Investor Conferences
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive...
May 10, 2021 07:30 am ET
Intra-Cellular Therapies Reports First Quarter 2021 Financial Results and Provides Corporate Update
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the first quarter...
May 05, 2021 08:00 am ET
Intra-Cellular Therapies to Present at Two Upcoming Investor Conferences
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive...
May 04, 2021 08:00 am ET
Intra-Cellular Therapies to Host First Quarter 2021 Financial Results Conference Call and Webcast
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live...
May 03, 2021 07:30 am ET
Intra-Cellular Therapies Announces FDA Acceptance of CAPLYTA® (lumateperone) sNDAs for the Treatment of Bipolar Depression
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA)...
Apr 22, 2021 07:30 am ET
Intra-Cellular Therapies Announces Investor Webcast and Presentations on Lumateperone Programs at the Upcoming American Psychiatric Association (APA) Annual Meeting
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, announces lumateperone presentations at the upcoming American...
Apr 20, 2021 07:00 am ET
Intra-Cellular Therapies Announces Board of Director Nominations in Advance of 2021 Annual Meeting
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) today announced the nominations of Sir Michael Rawlins and Joel S. Marcus to stand for election to the Company’s board of directors at its 2021 annual meeting of stockholders, scheduled for June 21,...
Apr 12, 2021 07:30 am ET
Intra-Cellular Therapies Presents Data on Antitumor Effects of Phosphodiesterase I Inhibition in a Preclinical Colorectal Cancer Model at the 2021 American Association for Cancer Research (AACR) Annua
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) today announced a poster presentation on its PDE1 inhibitor program at the ongoing 2021 American Association for Cancer Research (AACR) Virtual Annual Meeting, which is being held from April 10 - 15,...
Feb 25, 2021 07:30 am ET
Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2020 Financial Results And Provides Corporate Update
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the fourth quarter...
Feb 24, 2021 07:30 am ET
Intra-Cellular Therapies Announces Expansion of its Pipeline with the Introduction of a New Molecular Entity, ITI-1284
ITI-1284 is a deuterated form of lumateperone delivered sublingually as an orally disintegrating tablet (ODT-SL). ITI-1284 ODT-SL may offer pharmacologic benefits and ease-of-use for patients, particularly in elderly populations. Phase 1 single...
Feb 22, 2021 08:00 am ET
Intra-Cellular Therapies Applies for FDA Approval of CAPLYTA® (lumateperone) for the Treatment of Bipolar Depression
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, announced that it has recently submitted supplemental New Drug...
Feb 19, 2021 08:00 am ET
Intra-Cellular Therapies to Present at the SVB Leerink 10th Annual Global Healthcare Conference
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer...
Feb 17, 2021 08:00 am ET
Intra-Cellular Therapies to Host Fourth Quarter and Full-Year 2020 Financial Results Conference Call and Webcast
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live...
Jan 21, 2021 08:00 am ET
CAPLYTA® (lumateperone) Open-Label Safety Switching Study in Patients with Schizophrenia Published in the Journal, Schizophrenia Research
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the publication of results from the CAPLYTA...
Jan 05, 2021 08:00 am ET
Intra-Cellular Therapies to Present at the 39th Annual J.P. Morgan Healthcare Conference
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer...
Dec 29, 2020 08:00 am ET
Intra-Cellular Therapies Announces the Initiation of Clinical Trials for ITI-LLAI, a Long-Acting Injectable Formulation of Lumateperone for the Treatment of Schizophrenia and for ITI-333, a Novel Trea
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the initiation of clinical programs for the...
Dec 09, 2020 08:00 am ET
Intra-Cellular Therapies Highlights Lumateperone Presentations at the 59th Annual Meeting of the American College of Neuropsychopharmacology
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced two presentations at the 59th Annual Meeting of...
Nov 30, 2020 08:00 am ET
Intra-Cellular Therapies to Present at the Evercore ISI 3rd Annual HealthCONx Conference
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer...
Nov 09, 2020 07:30 am ET
Intra-Cellular Therapies Reports Third Quarter 2020 Financial Results and Provides Corporate Update
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the third quarter...
Nov 04, 2020 08:00 am ET
Intra-Cellular Therapies to Host Third Quarter 2020 Financial Results Conference Call and Webcast
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live...
Oct 01, 2020 04:30 pm ET
Intra-Cellular Therapies Announces the Appointment of Dr. Suresh Durgam as Chief Medical Officer
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the promotion of Dr. Suresh Durgam to the...
Sep 15, 2020 08:00 am ET
Intra-Cellular Therapies to Present at the Morgan Stanley 18th Annual Global Healthcare Conference
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer...
Sep 14, 2020 08:00 am ET
Intra-Cellular Therapies to Present at the Cantor Virtual Global Healthcare Conference
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer...
Sep 10, 2020 08:30 pm ET
Intra-Cellular Therapies Prices Public Offering of Common Stock
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company, today announced the pricing of its previously announced underwritten public offering of 11,666,667 shares of its common stock at a public offering price of $30.00 per...
Sep 09, 2020 04:01 pm ET
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company, today announced that it has commenced an underwritten public offering of $350 million of shares of its common stock. In connection with the offering, Intra-Cellular...
Sep 09, 2020 07:00 am ET
Intra-Cellular Therapies Announces Positive Topline Results from Study 402 Evaluating Lumateperone as Adjunctive Therapy in Patients with Bipolar Depression
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced positive topline results from its Phase 3...
Aug 10, 2020 07:30 am ET
Intra-Cellular Therapies Reports Second Quarter 2020 Financial Results and Provides Corporate Update
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the second quarter...
Aug 04, 2020 08:00 am ET
Intra-Cellular Therapies to Host Second Quarter 2020 Financial Results Conference Call and Webcast
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live...
Jun 29, 2020 08:00 am ET
Intra-Cellular Therapies Announces Positive Top-line Results from ITI-214 Phase I/II Study in Patients with Heart Failure
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI) today announced topline results from Study ITI-214-104, a Phase I/II translational study of single ascending doses of ITI-214, a novel, selective phosphodiesterase-1 (PDE1) inhibitor, in patients with...
May 14, 2020 08:00 am ET
Intra-Cellular Therapies to Present at the 2020 RBC Capital Markets Global Healthcare Conference
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer...
May 13, 2020 04:15 pm ET
Intra-Cellular Therapies to Host Virtual Annual Meeting of Stockholders
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will hold its 2020 Annual Meeting of...
May 07, 2020 07:30 am ET
Intra-Cellular Therapies Reports First Quarter 2020 Financial Results and Provides Corporate Update
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the first quarter...
Apr 29, 2020 08:00 am ET
Intra-Cellular Therapies to Host First Quarter 2020 Financial Results Conference Call and Webcast
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live...
Apr 16, 2020 04:45 pm ET
Intra-Cellular Therapies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the grant to 266 new employees of inducement...
Apr 02, 2020 08:00 am ET
Intra-Cellular Therapies Initiates Promotional Activities for CAPLYTA™ (lumateperone) for the Treatment of Schizophrenia in Adults
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced it has successfully initiated its promotional...
Mar 23, 2020 07:30 am ET
Intra-Cellular Therapies Announces Availability of CAPLYTA™ (lumateperone) for Adult Patients with Schizophrenia
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that CAPLYTA (lumateperone) is now available to...
Mar 02, 2020 07:30 am ET
Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Corporate Update
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the fourth quarter and...
Feb 24, 2020 08:00 am ET
Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2019 Financial Results Conference Call and Webcast
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live...
Feb 21, 2020 04:15 pm ET
Intra-Cellular Therapies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the grant to four new employees of inducement...
Feb 20, 2020 05:00 pm ET
Pivotal Study of CAPLYTA™ (lumateperone) for the Treatment of Schizophrenia in Adults Published in JAMA Psychiatry
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, announced the publication of results from its CAPLYTA...
Feb 18, 2020 08:00 am ET
Intra-Cellular Therapies to Present at the 9th Annual SVB Leerink Global Healthcare Conference
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer...
Jan 07, 2020 09:47 pm ET
Intra-Cellular Therapies Prices Public Offering of Common Stock
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company, today announced the pricing of its previously announced underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $29.50 per...
Jan 06, 2020 04:06 pm ET
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company, today announced that it has commenced an underwritten public offering of 10,000,000 shares of its common stock. In connection with the offering, Intra-Cellular Therapies...
Jan 02, 2020 08:00 am ET
Intra-Cellular Therapies to Present at the 38th Annual J.P. Morgan Healthcare Conference
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is...
Dec 23, 2019 06:59 am ET
FDA Approves Intra-Cellular Therapies’ Novel Antipsychotic, CAPLYTA® (lumateperone) for the Treatment of Schizophrenia in Adults
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that CAPLYTA® (lumateperone) has been approved by the U.S. Food and...
Dec 12, 2019 07:30 am ET
Intra-Cellular Therapies Highlights Lumateperone Presentations at the 58th Annual Meeting of the American College of Neuropsychopharmacology
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced data featured yesterday during the 58th Annual Meeting of the American...
Dec 04, 2019 08:00 am ET
Intra-Cellular Therapies to Present Data on Lumateperone and ITI-333 at the 58th Annual Meeting of the American College of Neuropsychopharmacology
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that the Company will be presenting at the 58th Annual Meeting of the...
Nov 05, 2019 07:30 am ET
Intra-Cellular Therapies Provides Corporate Update and Reports Third Quarter 2019 Financial Results
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today provided a corporate update and announced its financial results for the third...
Oct 29, 2019 08:00 am ET
Intra-Cellular Therapies to Host Third Quarter 2019 Financial Results Conference Call and Webcast
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast discussion at 8:30...
Sep 30, 2019 08:00 am ET
Intra-Cellular Therapies to Present at the 2019 Cantor Global Healthcare Conference
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is...
Sep 25, 2019 07:30 am ET
Intra-Cellular Therapies Announces Progression to Higher Dose Cohort in ITI-214 Translational Medicine Study in Patients with Heart Failure
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI) today announced the successful completion of the second dose cohort (single dose of 30 mg administered orally) in Study ITI-214-104 (Study ‘104), a proof-of-mechanism, translational medicine study of...
Sep 10, 2019 07:30 am ET
Intra-Cellular Therapies Provides Lumateperone Regulatory Update
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has informed the...
Aug 07, 2019 08:00 am ET
Intra-Cellular Therapies Provides Corporate Update and Reports Second Quarter 2019 Financial Results
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today provided a corporate update and announced its financial results for the second...
Aug 06, 2019 08:00 am ET
Intra-Cellular Therapies to Present at the Canaccord Genuity 39th Annual Growth Conference
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is...
Aug 05, 2019 07:30 am ET
Intra-Cellular Therapies to Host Conference Call to Provide Regulatory Update Following Recent Meeting with FDA
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that it recently met with the U.S. Food and Drug Administration (FDA)...
Jul 23, 2019 07:30 pm ET
Intra-Cellular Therapies Provides Update on FDA Advisory Committee Meeting for Lumateperone for the Treatment of Schizophrenia
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has cancelled the...
Jul 08, 2019 07:00 am ET
Intra-Cellular Therapies Announces Positive Top-line Results from a Phase 3 Trial of Lumateperone in Patients with Bipolar Depression
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced top-line results from two Phase 3 clinical trials (Study 401 and Study...
Jul 02, 2019 08:00 am ET
Intra-Cellular Therapies Appoints Karen Patruno Sheehy, Esq. as Senior Vice President, Chief Compliance Officer
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced the appointment of Karen Patruno Sheehy, Esq. as Senior Vice President,...
Jun 19, 2019 08:00 am ET
Intra-Cellular Therapies to Present at JMP Securities Life Sciences Conference
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is...
Jun 13, 2019 08:55 am ET
Intra-Cellular Therapies Announces FDA Advisory Committee Meeting to Review the NDA for Lumateperone for the Treatment of Schizophrenia in Adults
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that the  U.S. Food and Drug Administration (FDA) has announced a...
May 30, 2019 08:00 am ET
Intra-Cellular Therapies to Present at Jefferies 2019 Global Healthcare Conference
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is...
May 16, 2019 08:00 am ET
Intra-Cellular Therapies to Present at 2019 RBC Capital Markets Global Healthcare Conference
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is...
May 15, 2019 08:00 am ET
Intra-Cellular Therapies Announces Presentations on Lumateperone Schizophrenia Program at the American Psychiatric Association (APA) Annual Meeting
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, announced the presentation of posters highlighting the lumateperone program in...
May 08, 2019 07:30 am ET
Intra-Cellular Therapies Reports First Quarter 2019 Financial Results and Provides Corporate Update
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the first quarter ended March 31, 2019, and...
May 02, 2019 08:00 am ET
Intra-Cellular Therapies to Host First Quarter 2019 Financial Results Conference Call and Webcast
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI) a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast discussion at 8:30...
Apr 16, 2019 08:00 am ET
Intra-Cellular Therapies Mourns the Passing of Co-Founder and Nobel Laureate, Dr. Paul Greengard
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, mourns the passing of our co-founder, Dr. Paul Greengard, a neuroscientist and Nobel...
Apr 15, 2019 07:00 am ET
Intra-Cellular Therapies Presents Additional Results From Long-term Open Label Safety Study of Lumateperone at the 2019 Congress of the Schizophrenia International Research Society
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced additional results from its open-label safety switching study (Study...
Apr 10, 2019 07:25 am ET
Analysis: Positioning to Benefit within The Allstate, Seattle Genetics, Intra-Cellular Therapies, AMN Healthcare Services, AVX, and DURECT — Research Highlights Growth, Revenue, and Consolidated Resul
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of The Allstate Corporation (NYSE:ALL), Seattle Genetics, Inc. (NASDAQ:SGEN),...
Apr 09, 2019 08:00 am ET
Intra-Cellular Therapies Announces Presentation of Lumateperone Long-term Open Label Safety Study at the 2019 Congress of the Schizophrenia International Research Society
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced plans to present analyses from its open-label safety switching study...
Mar 26, 2019 07:00 am ET
Intra-Cellular Therapies Continues to Strengthen Its Commercial Leadership Team; John A. Bardi Appointed as Senior Vice President, Market Access, Policy and Government Affairs
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced the appointment of John A. Bardi as Senior Vice President for Market...
Mar 05, 2019 08:00 am ET
Intra-Cellular Therapies to Present at The Cowen and Company 39th Annual Health Care Conference
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is...
Feb 27, 2019 07:30 am ET
Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Corporate Update
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the fourth quarter and year ended December...
Feb 21, 2019 08:00 am ET
Intra-Cellular Therapies to Present at the 8th Annual SVB Leerink Global Healthcare Conference
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is...
Feb 20, 2019 08:00 am ET
Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2018 Financial Results Conference Call and Webcast
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast discussion at 8:30...
Feb 19, 2019 07:40 am ET
Detailed Research: Economic Perspectives on Tesla, Kura Oncology, ASML Holding N.V, Applied Industrial Technologies, Raven Industries, and Intra-Cellular Therapies — What Drives Growth in Today's Comp
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Tesla, Inc. (NASDAQ:TSLA), Kura Oncology, Inc. (NASDAQ:KURA), ASML Holding...
Jan 03, 2019 08:00 am ET
Intra-Cellular Therapies to Present at the 37th Annual J.P. Morgan Healthcare Conference
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is...
Dec 30, 2018 02:26 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intra-Cellular Therapies, Inc. - ITCI
Pomerantz LLP is investigating claims on behalf of investors of Intra-Cellular Therapies, Inc. (“Intra-Cellular” or the “Company”) (NASDAQ: ITCI) Investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext....
Dec 18, 2018 01:01 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intra-Cellular Therapies, Inc. - ITCI
NEW YORK, Dec. 18, 2018 /CNW/ -- Pomerantz LLP is investigating claims on behalf of investors of Intra-Cellular Therapies, Inc. ("Intra-Cellular" or the "Company") (NASDAQ: ITCI) Investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980.
Dec 18, 2018 01:01 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intra-Cellular Therapies, Inc. - ITCI
NEW YORK, Dec. 18, 2018 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Intra-Cellular Therapies, Inc. ("Intra-Cellular" or the "Company") (NASDAQ: ITCI) Investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980.
Dec 18, 2018 01:00 pm ET
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Intra-Cellular Therapies, Inc. (ITCI)
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Intra-Cellular Therapies, Inc. ("Intra-Cellular " or the “Company") (NASDAQ: ITCI). Such investors are encouraged to obtain...
Dec 18, 2018 08:30 am ET
Intra-Cellular Therapies Announces Update on ITI-007-201 Clinical Trial for Treatment of Agitation in Patients with Probable Alzheimer's Disease
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced an independent data monitoring committee (DMC) has completed a...
Dec 11, 2018 05:30 pm ET
Intra-Cellular Therapies Announces Favorable Results From Long-Term Open-Label Safety Switching Study With Lumateperone in Patients with Schizophrenia at the 57th Annual Meeting of the American Colleg
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced favorable results from  the second part  of its open-label safety...
Dec 11, 2018 07:00 am ET
Intra-Cellular Therapies Announces FDA Acceptance of New Drug Application for Lumateperone for the Treatment of Schizophrenia
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has accepted for...
Nov 07, 2018 07:00 am ET
Intra-Cellular Therapies Provides Corporate Update and Reports Third Quarter 2018 Financial Results
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today provided a corporate update and announced its financial results for the third...
Nov 01, 2018 08:00 am ET
Intra-Cellular Therapies to Host Third Quarter 2018 Financial Results Conference Call and Webcast
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI) a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast discussion at 8:30...
Oct 25, 2018 07:20 am ET
Investor Expectations to Drive Momentum within Tribune Media, Intra-Cellular Therapies, Icahn Enterprises, NVE, PetMed Express, and United Fire Group — Discovering Underlying Factors of Influence
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Tribune Media Company (NYSE:TRCO), Intra-Cellular Therapies Inc....
Oct 23, 2018 07:00 am ET
Intra-Cellular Therapies Announces Favorable Safety Profile for ITI-214 in a Phase 1/2 Clinical Trial in Patients with Parkinson’s Disease
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) today announced topline results from the Company’s Phase 1/2 clinical study evaluating ITI-214, its potent and selective phosphodiesterase 1 (PDE1) inhibitor, in patients with mild-to-moderate...
Oct 17, 2018 08:00 am ET
Intra-Cellular Therapies Presents Results from ITI-214 Phase 1/2 Clinical Trial in Patients with Parkinson’s Disease at 2018 American Neurological Association Annual Meeting
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced it will present top line results from the Company’s Phase 1/2 clinical...
Oct 16, 2018 08:00 am ET
Intra-Cellular Therapies Appoints Mark Neumann as Executive Vice President, Chief Commercial Officer
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced the appointment of Mark Neumann as Executive Vice President, Chief...
Sep 28, 2018 07:00 am ET
Intra-Cellular Therapies Completes Submission of New Drug Application for Lumateperone for Treatment of Schizophrenia
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that the Company has completed the rolling submission of its New Drug...
Sep 26, 2018 08:00 am ET
Intra-Cellular Therapies to Present at the Cantor Fitzgerald Global Healthcare Conference
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system ("CNS") disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is...
Sep 25, 2018 07:00 am ET
Intra-Cellular Therapies Appoints Michael Olchaskey as Senior Vice President, Head of Regulatory Affairs
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, announced the appointment of Michael Olchaskey, PharmD as Senior Vice President, Head...
Sep 05, 2018 07:55 am ET
New Research: Key Drivers of Growth for Intra-Cellular Therapies, The, Bassett Furniture Industries, NVE, Equity Bancshares, and Cable One — Factors of Influence, Major Initiatives and Sustained Produ
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Intra-Cellular Therapies Inc. (NASDAQ:ITCI), The Bancorp, Inc....
Aug 20, 2018 08:00 am ET
Intra-Cellular Therapies Appoints Dr. Suresh Durgam as Senior Vice President, Late Stage Clinical Development and Medical Affairs
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, announced the expansion of the senior leadership team with the appointment of Suresh...
Aug 15, 2018 07:35 am ET
Detailed Research: Economic Perspectives on Neos Therapeutics, Federated National Holding, FutureFuel, Golden Entertainment, Intra-Cellular Therapies, and HTG Molecular Diagnostics — What Drives Growt
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Neos Therapeutics, Inc. (NASDAQ:NEOS), Federated National Holding Company...
Aug 02, 2018 07:09 am ET
Intra-Cellular Therapies Provides Corporate Update and Reports Second Quarter 2018 Financial Results
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today provided a corporate update and announced its financial results for the second...
Jul 26, 2018 08:00 am ET
Intra-Cellular Therapies to Host Second Quarter 2018 Financial Results Conference Call and Webcast
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI) a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced day announced that it will host a conference call and live webcast...
Jul 23, 2018 07:00 am ET
Intra-Cellular Therapies Announces Publication Highlighting ITI-214 Mechanism of Action and Describing Positive Results in Preclinical Models of Heart Failure
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI) today announced the online publication of a report in the journal Circulation describing the mechanism of action of its phosphodiesterase (PDE) Type 1 inhibitor, ITI-214, and its potential use for the...
Jun 06, 2018 07:00 am ET
Intra-Cellular Therapies Initiates Rolling Submission of New Drug Application for Lumateperone for Treatment of Schizophrenia
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced the initiation of a rolling submission of its New Drug Application...
May 31, 2018 08:00 am ET
Intra-Cellular Therapies Presents Data on Symptom Improvement by Lumateperone on Negative Symptoms, Depression, and Social Function in Patients with Schizophrenia at the American Society of Clinical P
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, announced presentations on lumateperone at the American Society of Clinical...
May 30, 2018 08:00 am ET
Intra-Cellular Therapies to Present at the Jefferies 2018 Global Healthcare Conference
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system ("CNS") disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is...
May 29, 2018 08:00 am ET
Intra-Cellular Therapies Announces Presentations on Lumateperone at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, announced poster presentations at the upcoming American Society of Clinical...
May 24, 2018 08:25 am ET
New Research: Key Drivers of Growth for CSW Industrials, Cavco Industries, Intra-Cellular Therapies, Atrion, QAD, and A V Homes — Factors of Influence, Major Initiatives and Sustained Production
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of CSW Industrials, Inc. (NASDAQ:CSWI), Cavco Industries, Inc. (NASDAQ:CVCO),...
May 09, 2018 08:00 am ET
Intra-Cellular Therapies to Present at the Bank of America Merrill Lynch 2018 Health Care Conference
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system ("CNS") disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is...
May 04, 2018 08:00 am ET
Intra-Cellular Therapies Announces Presentations on Lumateperone at Two Upcoming Medical Conferences
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, announced presentations on lumateperone at the 2018 American Psychiatric...
May 03, 2018 07:00 am ET
Intra-Cellular Therapies Reports First Quarter 2018 Financial Results and Provides Corporate Update
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the first quarter ended March 31, 2018 and...
Apr 26, 2018 08:00 am ET
Intra-Cellular Therapies Presents Data on ITI-214 at the 2018 American Academy of Neurology Annual Meeting
Phase 1/2 clinical trial in patients with Parkinson's disease (PD) expanded to add additional cohort.
Apr 02, 2018 08:20 am ET
Recent Analysis Shows Eagle Bulk Shipping, QCR, Intra-Cellular Therapies, PGT, Northeast, and Ferrellgas Partners Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, April 02, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Eagle Bulk Shipping Inc. (NASDAQ:EGLE), QCR...
Mar 13, 2018 07:30 am ET
Intra-Cellular Therapies Announces Positive Pre-NDA Meeting with FDA for Lumateperone for the Treatment of Schizophrenia
NEW YORK, March 13, 2018 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that the Company had a positive pre-New Drug Application...
Mar 08, 2018 08:00 am ET
Intra-Cellular Therapies to Present at the Cowen and Company 38th Annual Health Care Conference
NEW YORK, March 08, 2018 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system ("CNS") disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman,...
Mar 01, 2018 07:00 am ET
Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update
NEW YORK, March 01, 2018 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the fourth quarter and year...
Feb 22, 2018 08:00 am ET
Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2017 Financial Results Conference Call and Webcast
NEW YORK, Feb. 22, 2018 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI) a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live...
Feb 15, 2018 08:00 am ET
UPDATE - Intra-Cellular Therapies to Present at RBC Capital Markets 2018 Global Healthcare Conference
NEW YORK, Feb. 15, 2018 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI) a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman,...
Feb 07, 2018 08:00 am ET
Intra-Cellular Therapies to Present at Upcoming Investor Conferences
NEW YORK, Feb. 07, 2018 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI) a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that it will present at the following upcoming investor...
Jan 30, 2018 07:40 am ET
Research Report Identifies Shutterstock, Intra-Cellular Therapies, ConforMIS, Jack Henry & Associates, Instructure, and WEX with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, Jan. 30, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Shutterstock, Inc. (NYSE:SSTK), Intra-Cellular Therapies Inc....
Jan 10, 2018 02:40 pm ET
Newman Ferrara LLP Announces Corporate Governance Investigation of Intra-Cellular Therapies, Inc. - ITCI
Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Intra-Cellular Therapies, Inc. (“Intra-Cellular Therapies” or the “Company”) (NASDAQ:ITCI) into potential breaches of fiduciary duty by the Company’s Board of Directors (the “Board”).
Jan 02, 2018 08:00 am ET
Intra-Cellular Therapies to Present at the 36th Annual J.P. Morgan Healthcare Conference
NEW YORK, Jan. 02, 2018 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman,...
Dec 07, 2017 08:00 am ET
Intra-Cellular Therapies Presents Data on Lumateperone, ITI-214 and ITI-333 at the 56th Annual Meeting of the American College of Neuropsychopharmacology
NEW YORK, Dec. 07, 2017 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced four poster presentations at the 56th Annual Meeting of...
Nov 27, 2017 08:00 am ET
Intra-Cellular Therapies to Participate at the 29th Annual Piper Jaffray Healthcare Conference
NEW YORK, Nov. 27, 2017 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system ("CNS") disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman,...
Nov 20, 2017 07:00 am ET
Intra-Cellular Therapies Receives FDA Fast Track Designation for Lumateperone for the Treatment of Schizophrenia
NEW YORK, Nov. 20, 2017 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has...
Nov 14, 2017 08:00 am ET
Intra-Cellular Therapies Presents Data on Mechanism of Action of Lumateperone and ITI-214 at the 2017 Society for Neuroscience (SfN) Annual Meeting
NEW YORK, Nov. 14, 2017 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced poster presentations related to its lumateperone and ITI-214 development...
Nov 13, 2017 08:00 am ET
Intra-Cellular Therapies Expands Its Executive Team with the Appointment of Dr. Andrew Satlin as Executive Vice President and Chief Medical Officer
NEW YORK, Nov. 13, 2017 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, announced that Andrew Satlin M.D. has joined the company as Executive...
Nov 08, 2017 07:30 am ET
Intra-Cellular Therapies Reports Third Quarter 2017 Financial Results and Provides Corporate Update
NEW YORK, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the third quarter ended September...
Nov 03, 2017 08:00 am ET
Intra-Cellular Therapies to Host Third Quarter 2017 Financial Results Conference Call and Webcast
NEW YORK, Nov. 03, 2017 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live...
Oct 02, 2017 04:01 pm ET
Intra-Cellular Therapies Announces Closing of $150 Million Public Offering of Common Stock
NEW YORK, Oct. 02, 2017 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company, today announced the completion of its previously announced underwritten public offering of 9,677,419 shares of its common stock at a public offering price of $15.50 per share. All of the shares in the offering were sold by Intra-Cellular Therapies, with gross proceeds to Intra-Cellular of approximately $150 million and net proceeds of approximately $141 million, after deducting underwriting discounts and commissions and estimated offering expenses. In addition, Intra-Cellula...
Sep 26, 2017 04:01 pm ET
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
NEW YORK, Sept. 26, 2017 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company, today announced that it has commenced an underwritten public offering of $150 million of shares of its common stock. In connection with the offering, Intra-Cellular Therapies intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. All of the shares in the offering will be sold by Intra-Cellular Therapies....

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.